Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

被引：0

作者：

N. Masuda

M. Toi

N. Yamamoto

H. Iwata

K. Kuroi

H. Bando

S. Ohtani

T. Takano

K. Inoue

Y. Yanagita

H. Kasai

S. Morita

T. Sakurai

S. Ohno

机构：

[1] NHO Osaka National Hospital,Department of Surgery, Breast Oncology

[2] Kyoto University Graduate School of Medicine,Department of Surgery (Breast Surgery)

[3] Chiba Cancer Center,Division of Breast Surgery

[4] Aichi Cancer Center Hospital,Department of Breast Oncology

[5] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Department of Breast Surgery

[6] University of Tsukuba,Breast and Endocrine Surgery, Faculty of Medicine

[7] Hiroshima City Hiroshima Citizens Hospital,Department of Breast Surgery

[8] Toranomon Hospital,Department of Medical Oncology

[9] Saitama Cancer Center,Division of Breast Oncology

[10] Gunma Prefectural Cancer Center,Department of Breast Oncology

[11] Kyoto University Hospital,Institute for Advancement of Clinical and Translational Science

[12] Kyoto University Graduate School of Medicine,Department of Biomedical Statistics and Bioinformatics

[13] Kyoto University Hospital,Department of Diagnostic Pathology

[14] NHO Kyushu Cancer Center,Clinical Research Institute

来源：

Breast Cancer | 2018年 / 25卷

关键词：

Anti-HER2 therapy; Lapatinib; Paclitaxel; Phase II study; Trastuzumab;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：407 / 415

页数：8

共 90 条

[1]

Slamon DJ(2001)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783-792

[2]

Leyland-Jones B(2005)Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673-1684

[3]

Shak S(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672

[4]

Fuchs H(2010)Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 377-384

[5]

Paton V(2011)pCR as a surrogate in HER2-positive patients treated with trastuzumab Cancer Res 71 64s-2743

[6]

Bajamonde A(2006)Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733-640

[7]

Romond EH(2012)Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 379 633-1192

[8]

Perez EA(2013)Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial Lancet Oncol 14 1183-899s

[9]

Bryant J(2013)Clinical and translational results of CALGB 40601: a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer J Clin Oncol 31 500-870s

[10]

Suman VJ(2005)Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations Clin Cancer Res 11 889s-5537

← 1 2 3 4 5 6 7 8 9 →